tradingkey.logo

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 And Extends Cash Runway

ReutersJan 20, 2026 12:12 PM

- Boundless Bio Inc BOLD.O:

  • BOUNDLESS BIO ADVANCES NOVEL KINESIN DEGRADER PROGRAM BBI-940 AND EXTENDS CASH RUNWAY

  • BOUNDLESS BIO INC: BBI-940 IND ACCEPTED; INITIATION OF FIRST-IN-HUMAN CLINICAL TRIAL ON TRACK FOR FIRST HALF OF 2026

  • BOUNDLESS BIO INC: PORTFOLIO PRIORITIZATION, INCLUDING DISCONTINUATION OF POTENTIATE TRIAL, EXTENDS OPERATING RUNWAY INTO H2 2028

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI